Related Experiment Video
Updated: Jan 4, 2026

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
Published on: May 4, 2017
Biosimilar Filgrastim Uptake And Costs Among Commercially Insured, Medicare Advantage
Pinar Karaca-Mandic1, Jessica Chang2, Ronald Go3
1Pinar Karaca-Mandic ( pkmandic@umn. edu ) is an associate professor in the Finance Department and academic director of the Medical Industry Leadership Institute, Carlson School of Management, University of Minnesota, in Minneapolis.
Abstract:
In 2015 the Food and Drug Administration approved filgrastim-sndz (Zarxio), the first US biosimilar. Following rapid uptake, by March 2018 filgrastim-sndz accounted for 47 percent of filgrastim administrations among commercially insured and 42 percent among Medicare Advantage beneficiaries. The initial cost difference between the originator and biosimilar was 31 percent in the former population but negligible in the latter.
Related Concept Videos
Drug Products: Biologics, Biosimilars and Interchangeables
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
Bioequivalence: Overview
Bioequivalence of Drugs: Drugs with Multiple Indications
Bioavailability: Overview
Bioequivalence studies: Biowaivers

